Click below to see a May 9, 2019 article that links ticagrelor (Brilinta) antiplatelet therapy with its putative anti-gram-positive bacterial property, including Methacillin-resistant Staph aureus and Vancomycin-resistant enterococcus. It appears that platelets are able to sequester the drug in sites of infection.
Posts - Antiplatelet Therapy
May 18, 2019 11:57am
Apr 22, 2019 1:02pm
I've attached a pre-pub article describing a phase I trial of ACT017, a novel antiplatelet antibody fragment specific for glycoprotein VI, a platelet membrane collagen receptor. The manufacturers propose that ACT017 infusion can suppress platelet activity as part of coronary artery disease therapy with minimal bleeding risk. Clip or tap the citation for full information:
Apr 16, 2019 9:11am
Poor old aspirin has again lost ground. Here's an editorial from the January, 2019 issue of European Heart Journal describing a meta-analysis of aspirin's lack of efficacy in subjects who have no cardiovascular disease risk factors:
Feb 24, 2019 4:13pm
Do any Fritsma Factor participants have experience with the platelet aggregation effects of eptifibatide (integrelin), or of any of the GP IIb/IIIa inhibitors. Do you have experience with the Werfen Accumetrics VerifyNow IIb/IIIa assay? If so, please comment below or email email@example.com.